S2 Ep39: Medical Crossfire: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

PER Podcast Sessions

Content provided by PER Spectives and PER® Spectives. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PER Spectives and PER® Spectives or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

1M ago 21:36

MP3•Episode home

Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Gabriela Hobbs, MD; John O. Mascarenhas, MD; and Naveen Pemmaraju, MD; discuss recent advances in therapies for myelofibrosis (MF), polycythemia vera (PV), and essential thrombocytopenia (ET).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
· Analyze the latest data on current and emerging therapies for MF, PV, and ET
· Create an evidence-based treatment plan for a patient with MF, PV, or ET that balances patient-, disease-, and treatment-related considerations
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from Geron, Incyte Corporation, and PharmaEssentia.

Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 5231
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Faculty:
Gabriela Hobbs, MD
Assistant Professor
Harvard Medical School
Clinical Director, Leukemia Service
Massachusetts General Hospital
Cambridge, MA
Disclosures: Advisor: Bristol Myers Squibb, GSK, Incyte, Novartis, Pfizer, Sobi; Consultant: Cogent, Merck, PharmaEssentia; Grant/Research Support: Incyte.
John Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Center of Excellence in Blood Cancers and Myeloid Disorders
Director, Adult Leukemia Program Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
New York, NY
Disclosures: Consultant: AbbVie, AJAX, Bristol Myers Squibb, CTI/SOBI, Disc, Galecto, Geron, GSK, Incyte, Kartos, Karyopharm, Keros, Merck, Novartis, Pfizer, PharmaEssentia, Roche, Sumitomo; Grant/Research Support: AbbVie, AJAX, Bristol Myers Squibb, CTI/SOBI, Geron, Incyte, Kartos, Karyopharm, Novartis, PharmaEssentia.
Naveen Pemmaraju, MD
Professor, Department of Leukemia
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Executive Director, MDACC Cancer Network for Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory Board: AbbVie, Bristol Myers Squibb Consulting, CTI BioPharma, GSK Consulting, Immunogen, Incyte, Johnson & Johnson, Karyopharm, Menarini-Stemline Group, MorphoSys, Pacylex, Protagonist; Board of Directors/Management: Dan's House of Hope; Consultant: AbbVie, Bristol Myers Squibb Consulting, CTI BioPharma, GSK Consulting, Immunogen, Incyte, Johnson & Johnson, Karyopharm, Menarini-Stemline Group, MorphoSys, Pacylex, Protagonist; Grant/Research Support: Sager Strong Foundation, United States Department of Defense (DOD); Speakers’ Bureau: AbbVie, Bristol Myers Squibb Consulting, CTI BioPharma, GSK Consulting, Immunogen, Incyte, Johnson & Johnson, Karyopharm, Menarini-Stemline Group, MorphoSys, Pacylex, Protagonist.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on applying best practices for identifying and managing treatment-related adverse events and strategies for implementing supportive care approaches to address symptom burden, go to https://www.gotoper.com/annual-oncology-meeting-25-mfpv-activity
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

60 episodes

#Science #Biology #Podcasting Education #Medicine #Spectives